Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a technical error in its website that led to an unrelated poster presentation being displayed on the Corporate Presentations page. The company clarified that the correct presentation of its breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting can be found on the Events page of its website. Anixa focuses on cancer treatment and prevention, collaborating with renowned institutions like Moffitt Cancer Center and Cleveland Clinic for its innovative therapies, including CAR-T technology and vaccines targeting triple negative breast cancer and ovarian cancer.
Anixa Biosciences (NASDAQ: ANIX) announced positive data from a Phase 1 trial of its breast cancer vaccine presented by the Cleveland Clinic. The data showed that immune responses were observed at all dose levels in vaccinated women, indicating varying levels of antigen-specific T cell responses. The trial aims to assess the vaccine's safety, determine the Maximum Tolerated Dose (MTD), and monitor immune responses in women at high risk of recurrence after having triple negative breast cancer (TNBC). Dr. Amit Kumar, CEO of Anixa, expressed optimism regarding the results, while Dr. G. Thomas Budd noted that the trial is not designed to confirm the efficacy of preventing recurrence. This promising development holds potential for future studies and advancements in breast cancer treatment.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that it will present results from its Phase 1a breast cancer vaccine trial on April 17, 2023, at the American Association for Cancer Research Annual Meeting in Orlando, FL. The vaccine, targeting triple-negative breast cancer using α-lactalbumin, is designed to activate the immune system against cancer cells expressing this 'retired' protein. This presentation will be significant for stakeholders following advancements in cancer immunotherapy. Anixa's portfolio also includes ovarian cancer immunotherapy programs in collaboration with Moffitt Cancer Center.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced it has no accounts at the recently collapsed Silicon Valley Bank, providing reassurance to shareholders and the investment community. The company focuses on cancer treatment and prevention, with ongoing projects in ovarian and breast cancer immunotherapy. Anixa partners with renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its novel CAR-T and vaccine technologies. These initiatives aim to target specific cancer types, particularly the aggressive triple-negative breast cancer and ovarian cancer.
On March 2, 2023, Anixa Biosciences (NASDAQ: ANIX) announced that its CEO, Dr. Amit Kumar, will present a corporate update at the company’s 2023 Annual Meeting of Stockholders on March 9 at 10:00 AM PST. The meeting will be virtual and accessible to shareholders and other interested parties via this link. Anixa focuses on developing treatments for cancer and infectious diseases, with collaborations involving cutting-edge technologies in cancer immunotherapy and COVID-19 therapeutics. The company emphasizes its unique business model of partnering with renowned research institutions.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent broadening the protection of its breast cancer vaccine technology. This patent, titled "Vaccine Adjuvants and Formulations," was developed at the Cleveland Clinic, making Anixa the exclusive licensee. The breast cancer vaccine targets Triple Negative Breast Cancer (TNBC), a particularly lethal form, and is currently in Phase 1 clinical trials. Data from these trials is expected to be presented at the American Association for Cancer Research annual meeting in April.